Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Neoadjuvant Adagrasib Alone or With Nivolumab May Improve pCR Rates in NSCLC

August 6th 2022

Neoadjuvant adagrasib as monotherapy or in combination with nivolumab may elicit improved pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer, according to the rationale for the phase 2 Neo-KAN study.

Biomarker Testing Provides a Way Forward for Increasingly Accurate Lung Cancer Diagnosis and Management

August 4th 2022

Giuseppe Lo Russo, MD, PhD, highlights the future role of liquid biopsy, the evolution of targeted therapies for KRAS G12C mutations, data to look forward to with EGFR-targeted agents, and the striking effects the COVID-19 pandemic has had on the mortality rates of patients with lung cancer.

Poziotinib Elicits Encouraging, Insertion Location–Specific Response Rates in EGFR Exon 20–Mutant NSCLC

August 4th 2022

Yasir Y. Elamin, MD, explained the rationale, design, and key findings of a phase 2 study evaluating poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer.

Pembrolizumab Post-Nephrectomy Extends Distant Metastasis-Free Survival, PFS2 in RCC

July 25th 2022

Toni K. Choueiri, MD, explains significant findings from the long-term efficacy analysis of the KEYNOTE-564 study and highlights the significance of these data for the field of RCC.

Molecular Testing Continues to Predict Treatment Efficacy in Ovarian Cancer

July 22nd 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the importance of helping patients make informed decisions about their care options and the future role of antibody-drug conjugate targets in the biomarker testing arena.

Increased Treatment Efficacy in p53-Mutated MCL Remains Elusive

July 21st 2022

Tycel Jovelle Phillips, MD, outlines the reasons why p53-mutated mantle cell lymphoma is difficult to treat and discusses potential future directions for the treatment of this subgroup of patients.

Rituximab Maintenance Therapy Continues to Provide Remission Benefit in MCL

July 20th 2022

Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.

BTK Inhibitor–Based Combinations May Improve the Efficacy of SOC Treatment in CNS Lymphoma

July 19th 2022

Avyakta Kallam, MBBS, discusses the benefits and shortcomings of the current standard of care in central nervous system lymphoma and expressed the importance of studying frontline targeted agents in this population.

Treatment Strategies Evolve With Increased Disease Specification in HER2+ Breast Cancer

July 15th 2022

Adrienne G. Waks, MD, highlights clinical trials that are studying emerging treatment escalation and de-escalation strategies in early stage HER2-positive breast cancer, elaborates on the future of immunotherapy in this setting, and explains the significance of establishing new biomarkers.

Seribantumab Demonstrates Positive Response Rates, Tolerability in NRG1 Fusion+ Solid Tumors

July 14th 2022

Daniel R. Carrizosa, MD, MS, discusses the design and important efficacy and safety findings from CRESTONE trial evaluating seribantumab and the importance of finding a targeted therapy for patients with solid tumors harboring NRG1 fusions.

Patient Selection May be Key for Leveraging Elacestrant in ER+/HER2- Breast Cancer

July 13th 2022

Francois-Clement Bidard, MD, PhD, highlights the benefits of elacestrant in chemotherapy-naïve patients and in those with ESR1 mutations, explains the results of a subgroup analysis done of the EMERALD trial in patients without prior chemotherapy, and voices his hopes for the future regarding other oral selective estrogen receptor degraders in development.

Machine Learning Increases Diagnostic Accessibility, Saves Time in Histopathology

July 13th 2022

R. Lor Randall, MD, FACS, shares the successes achieved so far with machine learning in histopathology, explained the positive effect this technology can have on institutions, and advocated for further use of technology to aid treatment advances.

ADCs and TKIs Plus Immunotherapy Signal the Future of Urothelial Carcinoma and RCC

July 12th 2022

Benjamin Garmezy, MD, discussed the positive trajectory of antibody-drug conjugates and immunotherapy in urothelial carcinoma, highlighting the importance of considering individual patient eligibility for treatments like first-line chemotherapy.

Individualized Care Drives Treatment Focus in AML, DLBCL, and CLL

July 11th 2022

Ehab Atallah, MD, explains how patient characteristics influence current treatment strategies in acute myeloid leukemia, how frontline pirtobrutinib may move toward use in chronic lymphocytic leukemia, and the growing evidence favoring CAR T-cell therapy as an effective treatment option in CLL.

Predictive ctDNA Testing Opens the Door for Increasingly Personalized Care in Colon Cancer

July 7th 2022

Ben Ho Park, MD, PhD, summarizes exciting data regarding circulating tumor DNA testing, including its ability to determine the benefits of adjuvant chemotherapy, its successful preliminary use in detecting cancer prior to recurrence, and how it may help guide future therapies.

New Findings in Breast Cancer Trials Call for Restructuring of Disease Subtypes

July 6th 2022

Gregory Vidal, MD, PhD, including the evolution of treatment options for HER2-low breast cancer, emerging antibody-drug conjugates in triple-negative disease, and the viability of HER3 as an emerging target in breast cancer

Tislelizumab Plus Chemotherapy Elicits Strong Survival Benefit in Esophageal Cancer

June 30th 2022

The combination of tislelizumab and chemotherapy demonstrated a superior overall survival benefit compared with chemotherapy alone in patients with metastatic or unresectable esophageal squamous cell carcinoma

Liso-cel Approval Provides Earlier, Expanded Access to CAR T-cell Therapy in Second-line LBCL

June 29th 2022

Second-line lisocabtagene maraleucel provides an earlier CAR T-cell treatment option that improves survival outcomes and produces a manageable safety profile in patients with relapsed/refractory large B-cell lymphoma, including those who are older and have comorbidities.

Teclistamab Elicits Survival Benefit vs Real-World Treatment in Multiple Myeloma

June 28th 2022

Teclistamab demonstrated superiority over physician’s choice of therapy for overall survival, progression-free survival, and time to next treatment in patients with relapsed/refractory multiple myeloma.

Obe-cel CAR T-cell Therapy Demonstrates Promising Safety Profile in Relapsed/Refractory B- ALL

June 28th 2022

Daniel DeAngelo MD, PhD, discusses the data seen with obecabtagene autoleucel as a novel treatment in the CAR T-cell arena, emphasizes unmet needs in B-cell acute lymphoblastic leukemia, and highlights important next steps in the study of obe-cel.